Navigation Links
New treatment for kala azar, the most deadly parasitic disease after malaria
Date:9/23/2011

[Nairobi, 23 September 2011] East Africa is fighting the worst kala azar outbreak in a decade. Collaboration across the region through the Leishmaniasis East Africa Platform (LEAP) has resulted in the development of a new combination therapy (SSG&PM) which is cheaper and nearly halves the length of treatment from a 30 day course of injections to 17 days. East African endemic countries are taking the necessary regulatory measures to use it in their programmes, but experts warn that without international funding or interest in supporting governments in the roll out, too few patients will benefit.

"The poorest of the poor, in the most remote villages are the ones who are wasting away from kala azar and who could benefit the most from a shorter more affordable treatment" said Dr. Monique Wasunna, Assistant Director, KEMRI, and Head, DNDi Africa. "Neglected diseases and patients mean that even when there are new treatments and hope, they are too far from the headlines and donor priorities to get support to governments. This is why we are calling for urgent action."

This week in Nairobi, over 100 clinical researchers and regional experts from Ministries of Health and drug regulatory authorities are meeting for the bi-annual LEAP Leishmaniasis East Africa Platform to see what is and is not working in the field and to find better ways to control the disease.

After 70 years of little improvement or change in the treatment of kala azar in Africa, LEAP and its partners have developed a new treatment: Sodium Stibogluconate & Paromomycin (SSG&PM) combination treatment. This is cheaper and nearly halves the length of treatment from the current 30 day course of injections to 17 days. It also cures the patient. Combination therapies help fight resistance to treatment. Countries around the region are in the process of registration and are ready to use the treatment, but need funding to control the disease.

Kala azar is another name given to visceral leishmaniasis (VL), a parasitic disease endemic in around 70 countries worldwide. South Sudan has the second highest number of cases after India. The disease is spread through the bite of a sandfly and is fatal without treatment. Approximately half a million people are infected with the disease and 50-60,000 die every year as a result of the infection. Patients suffer from irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anaemia.

"I have spent fifty years treating kala azar patients and researching this killer parasite and I know first-hand how desperately these poor patients and overburdened health workers need shorter, cheaper, and easier-to-use treatment," said Professor Ahmed Mohamed El Hassan, Emeritus Professor, Institute of Endemic Diseases University of Khartoum, Sudan. "Ideally for patients in such conditions, we need an oral treatment, such as those being tested or completely new drugs, but we are a long way from there and we need to make the most of this existing better treatment and find the funds to roll it out," he concluded.

In March 2010, the World Health Organization (WHO) Expert Committee on the Control of Leishmaniases recommended SSG&PM as first-line treatment for VL in East Africa. It is already being used to treat patients in the countries such as Sudan and South Sudan. Other affected countries are in the process of registering PM to combine it with the already registered SSG to get the treatment to patients.

"After 20 years, WHO has updated the guidelines for the control of leishmaniasis. This shows that there is greater collaboration and progress. Now countries need support to translate this into lives saved on the ground," said Dr. Merc Herrero, Disease Prevention and Control, Leishmaniasis National Control Programme, WHO Ethiopia.

The development of SSG&PM is the result of a collaborative partnership over a period of six years between DNDi, LEAP, and other partners including the National Control Programmes of Kenya, Sudan, Ethiopia, and Uganda, as well as Mdecins Sans Frontires (MSF) and the World Health Organization (WHO).


'/>"/>

Contact: Violaine Daellenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Related medicine news :

1. Heart drug offers possible treatment for patients facing respiratory failure
2. Elderly breast cancer patients risk treatment discrimination
3. University of Kentucky spinoff licensed to develop Alzheimers treatment
4. UT awarded NIH grants to study prevention and treatment of neurodegenerative and vascular diseases
5. Continued treatment for lupus may boost survival of those patients with end-stage kidney disease
6. Emergency treatment for heart attack improving but delays still occur
7. One-Third of Severe Heart Attack Patients Have Treatment Delays
8. Two Varicose Veins Treatments Equally Effective
9. T cells making brain chemicals may lead to better treatments for inflammation, autoimmune diseases
10. Estrogen treatment may help reverse severe pulmonary hypertension
11. Tailored Hepatitis C Therapy May Cut Treatment Time in Half
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... In any business, follow up is critical to ... dental team at presenting treatment, there will always be some patients who can’t or ... money on best practices when it comes to presenting treatment. After the patient ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to announce the launch of ... which will educate readers on how to take care of all aspects of their ... placed on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with ...
(Date:5/26/2017)... ... 2017 , ... The Radiology Business Management Association (RBMA) ... legislative activity and the latest regulatory concerns impacting RBMA members. The Legislative Education ... will continue through Monday, Sept. 11, at the Ritz-Carlton, Tysons Corner in Mclean, ...
(Date:5/26/2017)... ... 2017 , ... A new analysis of community health data reveals that four ... the Midwest. With the average cost of healthcare rising and the U.S. senior population ... quality and affordability of where they live. An annual 2017 report looked at a ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the Congressional ... passed the U.S. House on May 4, would result in 23 million Americans losing ... implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , “It ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... 3, 2017  Kalorama Information notes that transplant ... next year and this is projected to continue ... cell (HSCT) or bone marrow transplants require histocompatibility ... well-suited for this task. This according to a ... Information. The various PCR-based methodologies, Sanger sequencing and ...
(Date:5/2/2017)... and NEW YORK ... As the leading distributor of market intelligence, ... European Med Tech Reimbursement Consulting AB that ... Tech Reimbursement Consulting AB,s proprietary market analyses through the ... professionals around the world easy access to complete product ...
Breaking Medicine Technology: